185 THE PROTECT STUDY: EVEROLIMUS MONOTHERAPY vs. CALCINEURIN INHIBITOR-BASED THERAPY RESULTS IN PROGRESSIVE RENAL FUNCTION BENEFIT OVER 35 MONTHS IN LIVER TRANSPLANT RECIPIENTS

185 THE PROTECT STUDY: EVEROLIMUS MONOTHERAPY vs. CALCINEURIN INHIBITOR-BASED THERAPY RESULTS IN PROGRESSIVE RENAL FUNCTION BENEFIT OVER 35 MONTHS IN LIVER TRANSPLANT RECIPIENTS M. Sterneck, G. Kaiser, N. Richter, N. Heyne, F. Rauchfuss, P. Neuhaus, P. Schemmer, L. Fischer, E.M. Paulus, M. Mertens, H.J. Schlitt. University Medical Center Hamburg Eppendorf, Department of Hepatobiliary and Transplant Surgery, Hamburg, Essen University Hospital, Department of General, Visceral and Transplantation Surgery, Essen, Hannover Medical School (MHH), Clinic for General, Abdominal and Transplant Surgery, Hannover, University Hospital Tuebingen, Department of General, Visceral and Transplant Surgery, Tubingen, Jena University Hospital, Department of General, Abdominal and Vascular Surgery, Jena, Charite University Medical Center Berlin, Clinic for General, Adbominal and Transplant Surgery, Berlin, University Hospital Heidelberg, Department of General Visceral and Transplant Surgery, Heidelberg, Novartis Pharma, Nurnberg, University Hospital Regensburg, Department of Surgery, Regensburg, Germany E-mail: sterneck@uke.de